Prism

Prism BioLab is a clinical-stage biotechnology company headquartered in Japan that focuses on the development of small molecule inhibitors for protein-protein interactions (PPIs). The company's core strength lies in its proprietary PepMetics technology platform, which enables the design of small molecules that mimic secondary structures of proteins, such as alpha-helices and beta-turns. This approach allows the company to target intracellular signaling pathways that were previously considered undruggable. Their lead program, PRI-724, is a selective inhibitor of the Wnt/beta-catenin signaling pathway and is currently undergoing clinical trials for liver cirrhosis and various cancers. Prism BioLab has successfully formed strategic partnerships with several global pharmaceutical leaders to expand the application of its platform across multiple therapeutic areas.